TY - JOUR
T1 - Opportunities for improvement
T2 - anticoagulation in patients undergoing total knee or hip replacement
AU - Thorsberger, Mads
AU - Jensen, Thomas
AU - Olesen, Jonas
AU - Weeke, Peter
AU - Wahlsten, Liv
AU - Jensen, Per
AU - Gislason, Gunnar
AU - Torp-Pedersen, Christian
AU - Koeber, Lars
AU - Fosbøl, Emil
PY - 2015/11
Y1 - 2015/11
N2 - BACKGROUND: According to guidelines, initiation of pharmacological thromboprophylaxis after total knee or hip replacement is recommended and associated with improved patient outcomes. However, data on how these recommendations are followed in clinical practice are sparse.METHODS: All patients undergoing first-time total knee or hip replacement in Denmark 2008-2011 were identified. By cross-referencing Danish nationwide registries, quantitative use of anticoagulants administered orally and subcutaneously post-discharge was assessed by number of claimed prescriptions after surgery. Logistic regression analysis was used to identify factors associated with initiation of prophylaxis.RESULTS: A total of 50,389 patients were included in the study (median age 69, inter-quartile range 62-76). Novel oral anticoagulants were initiated in 14.7 % of the patients and heparins/fondaparinux in 2.3 % of the patients. The use of anticoagulants increased from 6.3 % in 2008 to 30.0 % of patients in 2011. Among patients initiating prophylaxis with a novel oral anticoagulant post-discharge, almost all were treated according to guidelines in terms of treatment duration. Factors significantly associated with an increased chance of prophylaxis among total hip replacement patients were: age (per 10-year increments) and female gender.CONCLUSIONS: Use of pharmacological thromboprophylaxis after total knee or hip replacement was low, but increasing during the study period. This is probably due to increased availability of novel oral anticoagulants. Further initiatives to increase guideline recommended use of prophylactic anticoagulation after orthopaedic surgery are warranted.
AB - BACKGROUND: According to guidelines, initiation of pharmacological thromboprophylaxis after total knee or hip replacement is recommended and associated with improved patient outcomes. However, data on how these recommendations are followed in clinical practice are sparse.METHODS: All patients undergoing first-time total knee or hip replacement in Denmark 2008-2011 were identified. By cross-referencing Danish nationwide registries, quantitative use of anticoagulants administered orally and subcutaneously post-discharge was assessed by number of claimed prescriptions after surgery. Logistic regression analysis was used to identify factors associated with initiation of prophylaxis.RESULTS: A total of 50,389 patients were included in the study (median age 69, inter-quartile range 62-76). Novel oral anticoagulants were initiated in 14.7 % of the patients and heparins/fondaparinux in 2.3 % of the patients. The use of anticoagulants increased from 6.3 % in 2008 to 30.0 % of patients in 2011. Among patients initiating prophylaxis with a novel oral anticoagulant post-discharge, almost all were treated according to guidelines in terms of treatment duration. Factors significantly associated with an increased chance of prophylaxis among total hip replacement patients were: age (per 10-year increments) and female gender.CONCLUSIONS: Use of pharmacological thromboprophylaxis after total knee or hip replacement was low, but increasing during the study period. This is probably due to increased availability of novel oral anticoagulants. Further initiatives to increase guideline recommended use of prophylactic anticoagulation after orthopaedic surgery are warranted.
KW - Aged
KW - Anticoagulants/administration & dosage
KW - Arthroplasty, Replacement, Hip/adverse effects
KW - Arthroplasty, Replacement, Knee/adverse effects
KW - Dabigatran/therapeutic use
KW - Denmark
KW - Female
KW - Follow-Up Studies
KW - Heparin, Low-Molecular-Weight/administration & dosage
KW - Humans
KW - Male
KW - Middle Aged
KW - Postoperative Complications/mortality
KW - Quality Improvement
KW - Registries
KW - Retrospective Studies
KW - Risk Assessment
KW - Rivaroxaban/administration & dosage
KW - Statistics, Nonparametric
KW - Survival Rate
KW - Treatment Outcome
KW - Venous Thromboembolism/etiology
U2 - 10.1007/s00776-015-0762-0
DO - 10.1007/s00776-015-0762-0
M3 - Journal article
C2 - 26293801
SN - 0949-2658
VL - 20
SP - 1036
EP - 1045
JO - Journal of Orthopaedic Science
JF - Journal of Orthopaedic Science
IS - 6
ER -